In this section, you can access to the latest technical information related to the FUTURE project topic.

FORMAS CRISTALINAS DE UN INHIBIDOR DE TLR7/TLR8.

This application relates to various crystalline forms of (S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyri din-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin- 1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ("hydrates"). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.


» Number: MX2020012259A (A)

» Publication Date: 29/01/2021

» Applicant: NOVARTIS AG?[CH]

» Inventor: LUSTENBERGER PHILIPP?[CH]; LI BIN (5)

» More Information

« Go to Technological Watch



AIMPLAS Instituto Tecnológico del Plástico

C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN

PHONE

(+34) 96 136 60 40

EMAIL

Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es